Ridgefield, CT, November 17, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a U.S. Department of Defense cohort analysis of the Military Health System database showing that non-valvular atrial fibrillation (NVAF) patients treated with Pradaxa® (dabigatran etexilate mesylate) in routine clinical care experienced reduced rates of stroke, major bleeding, death and other types of bleeding, along with increased lower gastrointestinal (GI) bleeding, compared to patients treated with warfarin.

INDIANAPOLIS, Feb. 19, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has accepted the recommendation of the ACCELERATE study academic executive committee, based on emerging science in the cardiovascular field, to extend the Phase 3 trial of the investigational medicine evacetrapib by approximately six months.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess alirocumab administered every four weeks, met their primary efficacy endpoints.

Medtronic, Inc. (NYSE: MDT) announced today that the U.S. Food and Drug Administration (FDA) has approved the company's IN.PACT Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) in the upper leg.

Merck, known as MSD outside the United States and Canada, today announced that the US Food and Drug Administration (FDA) has approved LIPTRUZET™(ezetimibe and atorvastatin) tablets.

Merck, known as MSD outside the United States and Canada, today announced that the US FDA has approved LIPTRUZET™(ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein (LDL) cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.

Sudden cardiac arrest, when the heart suddenly becomes unable to function properly, occurs in several hundred thousand individuals in the United States yearly.

Merck today announced the company is taking steps to suspend the availability of TREDAPTIVE™ (extended-release niacin/ laropiprant ) tablets worldwide. TREDAPTIVE is not approved for use in the United States.

Merck (NYSE: MRK ), known as MSD outside the United States and Canada, announced today that the US Food and Drug Administration (FDA) has acknowledged the resubmission of a New Drug Application (NDA) for ezetimibe and atorvastatin tablets, an investigational combination medicine.

Aegerion Pharmaceuticals, Inc. today announced that the US Food & Drug Administration (FDA) has approved JUXTAPID™ ( lomitapide ) capsules as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol ( LDL-C ), total cholesterol ( TC ), apolipoprotein B ( apo B) and non-high density lipoprotein cholesterol ( non-HDL ) in patients with homozygous familial hypercholesterolemia ( HoFH ).